PHAXIAM Therapeutics S.A. Total Liabilities

PHAXIAM Therapeutics S.A. (PHXM) currently reports a total liabilities of $26M as of December 2023. That compares with $22M in the prior-year period — up 15.1% year over year. Use the charts on this page to explore PHAXIAM Therapeutics S.A.'s total liabilities history and peer comparisons.

PHAXIAM Therapeutics S.A.'s total liabilities increased from $22M to $26M — a 15.1% year-over-year increase (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

PHAXIAM Therapeutics S.A. reported $26M in total liabilities as of December 2023. That compares with $22M in the prior-year period — up 15.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $26M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for PHAXIAM Therapeutics S.A., and consider following PHXM for alerts when major investors trade the stock.

PHAXIAM Therapeutics S.A. is classified in the Healthcare sector. On total liabilities, it currently shows $26M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PHXM with unrelated industries.